Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CGTX
- Price
- 0.39
- Stock movement up
- +0.04 (11.65%)
- Company name
- Cognition Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 16.37M
- Ent value
- 7.46M
- Price/Sales
- 44.01
- Price/Book
- 1.13
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -81.15%
- 3 year return
- -49.67%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-14
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CGTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 44.01 |
| Price to Book | 1.13 |
| EV to Sales | 20.04 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.55M |
| EPS (TTM) | -0.85 |
| FCF per share (TTM) | -0.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 372.00K |
| Gross profit (TTM) | 181.00K |
| Operating income (TTM) | -58.43M |
| Net income (TTM) | -34.27M |
| EPS (TTM) | -0.85 |
| EPS (1y forward) | -0.81 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.66% |
| Operating margin (TTM) | -15707.53% |
| Profit margin (TTM) | -9212.37% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 22.01M |
| Net receivables | 0.00 |
| Total current assets | 26.83M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 27.58M |
| Accounts payable | 1.90M |
| Short/Current long term debt | 580.00K |
| Total current liabilities | 12.71M |
| Total liabilities | 13.10M |
| Shareholder's equity | 14.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -25.55M |
| Capital expenditures (TTM) | 36.00K |
| Free cash flow (TTM) | -25.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -236.64% |
| Return on Assets | -124.26% |
| Return on Invested Capital | -233.61% |
| Cash Return on Invested Capital | -174.40% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.37 |
| Daily high | 0.40 |
| Daily low | 0.36 |
| Daily Volume | 690K |
| All-time high | 12.98 |
| 1y analyst estimate | 6.20 |
| Beta | 1.33 |
| EPS (TTM) | -0.85 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Jun 2025 |
Downside potential
Loading...
Downside potential data
| CGTX | S&P500 | |
| Current price drop from All-time high | -96.96% | -12.04% |
| Highest price drop | -97.54% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -82.02% | -11.07% |
| Avg time to new high | 442 days | 12 days |
| Max time to new high | 860 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
16.37M
Marketcap category
Small-cap
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Employees
25
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page